The startup develops a gene interference technology utilizing a proprietary RNA interference (RNAi) platform to achieve precise cellular targeting and effective reduction of disease-causing proteins. This technology specifically addresses the challenges of RNAi delivery in treating immunological and fibrotic diseases, enabling more effective therapies for chronic conditions.
Funding
$7.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current RNA interference (RNAi) delivery methods face challenges in achieving precise cellular targeting and effective reduction of disease-causing proteins, particularly in treating immunological and fibrotic diseases. This limitation hinders the development of effective therapies for chronic conditions.
Solution
siRNAgen Therapeutics is developing a gene interference technology that leverages a proprietary RNAi platform, SAMiRNA, to enhance cellular targeting and improve the reduction of disease-causing proteins. The SAMiRNA platform is designed to overcome the delivery challenges associated with RNAi-based therapeutics, especially in the context of immunological and fibrotic diseases. This technology aims to enable the creation of more effective therapies for various chronic conditions by improving the precision and efficacy of RNAi delivery.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing novel therapies for immunological and fibrotic diseases.
Features
- Proprietary SAMiRNA platform for enhanced RNAi delivery.
- Technology designed for precise cellular targeting.
- Aims to improve the reduction of disease-causing proteins.
- Specifically addresses challenges in treating immunological and fibrotic diseases.